Background: This meta-analysis aimed to assess the cardiac safety profile of domperidone treatment for the risk of cardiovascular (CV) event and QT prolongation. Methods: Data from nine studies involving 101,155 patients were used for the analysis of CV event risk, while data from eight studies involving 390 patients were used for the analysis of QT prolongation risk.
Introduction
Domperidone (DMP), a peripheral dopamine D 2 -receptor antagonist with prokinetic and antiemetic properties, has been broadly prescribed for nausea and vomiting, gastroparesis and gastroesophageal reflux disease and stimulation of breast milk production. [1] [2] [3] [4] DMP and metoclopramide (MCP) are dopamine antagonists with a strong affinity for dopamine receptors in the central as well as peripheral nervous systems, and specifically the gastrointestinal tract, and thus they act as antiemetics at the chemoreceptor trigger zone and as prokinetics in the upper gastrointestinal tract to accelerate gastric emptying. 5 Although MCP readily crosses the blood-brain barrier leading to central nervous system side effects in up to 40% of patients ranging from somnolence to extrapyramidal symptoms, DMP poorly penetrates the bloodbrain barrier but maintains a powerful antiemetic effect at the chemoreceptor trigger zone level as well as its peripheral prokinetic properties. 5 Accordingly, DMP is considered a safer alternative to MCP in patients with intolerance to MCP treatment or those requiring long-term therapy for upper gastrointestinal motility problems in whom nausea and vomiting are prominent. 5 Although the safety profile of DMP is more acceptable than MCP and cisapride, 3 hazardous cardiovascular (CV) adverse effects are considered likely because of its narrow therapeutic index. 6, 7 The putative mechanism by which DMP delays cardiac repolarization and prolongs the QT interval is considered to involve blockage of IKr, the rapid component of the delayed rectifier potassium current, ether-a-go-go-related gene, leading to a prolongation of cardiac repolarization. [8] [9] [10] [11] A prolonged QT interval is considered a predictive, noninvasive risk factor for sudden cardiac death (SCD) since a delay in ventricular repolarization can lead to a more chaotic cardiac depolarization/repolarization cycle and can provoke arrhythmias with high risk of SCD, such as ventricular fibrillation and torsade de pointes. 5, 12 Published data on prolongation of QT interval and potential adverse CV events such as ventricular arrhythmias (VAs) and/or SCD under DMP treatment are largely limited to case reports and case-control studies alongside inconsistent findings. 2, 4, 5, 7, 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Therefore, a need for further investigation with large clinical trials is emphasized to address the safety profile of DMP more appropriately. 2, 5 Until such a study is published, to evaluate this serious claim, we aimed with the present meta-analysis to assess the association between different doses of DMP and CV events and QT prolongation risk in comparison to MCP.
Materials and methods

Search strategy and study selection
The PubMed database was searched using the following terms: (a) ''domperidone'' AND at least one of the terms ''cardiovascular, QT, death, arrhythmia'' and (b) ''domperidone'' AND ''metoclopramide'' AND ''cardiovascular,'' in titles and abstracts limited to articles published in English and studies in humans. The literature was searched from inception to June 30, 2018 . The authors evaluated the title and abstract of each article separately. The full text of 115 articles was reached.
Study selection
We included studies that met the following criteria: (1) a clinical study published as an original article; (2) exposure of interest was oral DMP treatment, (3) outcome of interest was a CV event or QT prolongations, and (4) available odds ratio (OR) with 95% confidence interval (CI) (or data to calculate these) was provided. Exclusion criteria were: (1) preclinical studies, (2) case reports and meta-analyses, and (3) lack of sufficient information on CV events or QT interval measurement.
Publication bias
Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, classic fail-safe N analysis, Begg's rank correlation and Egger's weighted regression tests. 33, 34 Heterogeneity assessment
The I 2 statistics of Higgins and Thompson was used to assess heterogeneity among studies. 35 I 2 values of 25%, 50% and 75% represent low, moderate and high heterogeneity, respectively. 36 The presence of heterogeneity across studies was defined using Cochran's Q test with a 0.10 significance level. 37 
Quality of studies
The quality of studies was assessed using Jadad scoring 38 for clinical studies, using the Newcastle-Ottawa Scale for Case-Control Studies for case-control studies, and using the Newcastle-Ottawa Scale for Cohort Studies for single-arm clinical studies. 39, 40 Jadad scoring has three items with a score range of 0 to 5. The first item is related to randomization (0, nonrandomized; 1, randomized but the sequence of the randomization was not reported; 2, randomized appropriately). The second item is related to doubleblinding (0, not double-blinded; 1, double-blinded but the details were not reported; 2, appropriate doubleblinding techniques were performed). The third item is related to withdrawals and dropouts (0, number and reasons for withdrawals were not stated; 1, number and reasons for withdrawals were stated). An a priori cutoff value for Jadad score to include the studies was not set. 38 The Newcastle-Ottawa Scale for Case-Control studies is based on the selection of case and controls, comparability of cases and controls and ascertainment of exposure, while the Newcastle-Ottawa Scale for Cohort studies is based on the selection of cohorts, comparability of cohorts and assessment of outcome. ''High''-quality choices are identified with a star, with a maximum of one star for each item within the ''Selection'' and ''Exposure/Outcome'' categories and a maximum of two stars for ''Comparability.'' For case-control studies a statement of no history of disease or incident and demonstration that outcome of interest was not present at start of study earns a star, whereas for cohort studies, adequacy of follow-up of cohorts is based on assessment of the follow-up of the exposed and nonexposed cohorts to ensure that losses are not related to either the exposure or the outcome.
39,40
Statistical methods
ORs with a 95% CI for CV event risk were presented based on calculated risk (using raw data provided in each study) as well as adjusted risk obtained from original data provided in each study. Fixed-effects and random-effects models were applied to all comparisons to determine corresponding overall effect sizes and related CIs when heterogeneity was absent or evident, respectively. Only random-effects model findings are presented here since there was no significant difference between both models for all variables except for DMP vs MCP. For analysis of QT prolongation risk, event rates, difference between pretreatment and posttreatment means for QT interval values and Hedge's g, value with 95% CIs were used. All statistical analyses were performed with Comprehensive Meta-Analysis, v.2.2.064 (www.Meta-Analysis.com, USA). Summary statistics are expressed as mean AE standard deviation (SD), n (%) and 95% CI, where appropriate. A twosided p < 0.05 was considered statistically significant.
Results
Included studies
Of 115 studies initially selected, 98 studies were excluded because of inclusion of preclinical data (n ¼ 39), lack of data on the relationship of DMP with CV risk or QT prolongation (n ¼ 25), lack of original data or appropriate statistical analysis (n ¼ 19), inclusion of data on parenteral use of DMP (n ¼ 7), case reports (n ¼ 4), no data on CV risk or QT prolongation (n ¼ 3) and meta-analysis (n ¼ 1). Of 17 studies included in the meta-analysis, data from nine studies [17] [18] [19] [20] [21] [22] [23] [24] [25] were used to analyze DMP-related risk of a CV event, as well as for CV risk related to DMP vs MCP [17] [18] [19] 25 and related to different doses of DMP. 17, 18, 23, 25 Data from the remaining eight studies 3, 26, 32 were used to analyze DMP-related risk of QT prolongation. Figure 1 illustrates the corresponding flow diagram of the study selection.
Data on quality of studies are provided in Table 1 .
CV event risk
Characteristics of studies. Characteristics of studies 17, 25 selected for the analysis of DMP/MCP-related CV event risk are presented in Table 1 . All studies were Values in italic refer to data not provided in the publication but calculated using the other data available in the study, retrospective except two studies (one with crossover and the other is a case control in a small group of patients). Cardiac outcome analysis was based both on VA and SCD in three studies, 18, 21, 24 while on SCD per se in four studies, 17, 22, 23, 25 acute myocardial infarction risk in one study 19 and cardiac arrest accompanied with or without death in one study 20 (Table 1) . Supplementary Appendix 1(a) ).
Visual inspection of the funnel plot and Egger regression asymmetry test (intercept (95% CI Supplementary Appendix 1(b) ).
Visual inspection of the funnel plot and Egger regression asymmetry test (intercept (95% CI Supplementary Appendix 1(c) ).
QT prolongation risk
Characteristics of studies. Of the eight studies 3, [26] [27] [28] [29] [30] [31] [32] included in the meta-analysis, two studies 26, 27 investigated QT/QTc (TQT) studies, and the others 3, [28] [29] [30] [31] [32] were clinical studies of patients with a wide age scale ranging from newborns to adults (Table 1) .
DMP-QT prolongation risk: event rates. A meta-analysis of 390 patients from eight studies revealed no significant increase in QT prolongation event rates with DMP use (Table 3 Figure 3) .
Heterogeneity was noted for the outcome of the QT prolongation for difference between means (p ¼ 0.000, I
2 ¼ 76.8%), standardized difference between means Calculated by means of a meta-analytical approach.
Discussion
The present meta-analysis of studies with DMP and MCP treatments [17] [18] [19] 25 suggested a significantly lower CV event risk with DMP. When DMP treatment was compared with no treatment, a significant increase in CV event risk was suspected under DMP treatment based on adjusted risk in the overall analysis population. However, subgroup analysis of studies with different DMP doses 17, 18, 24, 25 confirmed that this seemingly significant increase in CV event risk under DMP treatment occurred only with higher daily doses (>30 mg/day), with no CV event risk attributable to DMP use at regular ( 30 mg/day) daily doses.
Hence, findings from the present meta-analysis suggest that DMP may not be associated with an overall CV event risk increase given the potential CV safety of the drug when used at lower doses ( 30 mg/day), while DMP also seems to offer a much more favorable cardiac safety profile than MCP at any dose in accordance with the literature. 3 CV risk attributable to DMP has been considered likely to differ with respect to subgroups of exposed individuals (higher in males and older individuals) as well as according to dosage (higher for doses >30 mg/day) of DMP. 2, 20, 21, 24, 41 These findings seem in accordance with regulatory restrictions introduced by the European Medicines Agency recommending DMP be used at a reduced dose in adults (up to 30 mg/day) and children (up to 0.75 mg/kg/day), for a restricted period (less than one week) and cautiously in high-risk groups such as the elderly (!60 years). 1 Accordingly, our findings seem to indicate an association of DMP treatment with lower CV risk as compared with MCP treatment and a dose-dependent increase in CV event risk with a 2.1 -to 3.1-fold increase in risk at doses >30 mg/day of MCP. This emphasizes a need for close monitoring for cardiac events and electrocardiogram (ECG) changes and adhering to appropriate cardiac risk monitoring protocols 5 in patients receiving DMP at daily doses exceeding 30 mg and weighing the risk not only in the context of clinical decisions but also based on alternatives. 2 Nonetheless, given that the present meta-analysis was based exclusively on retrospective studies and the lack of studies with a longitudinal, prospective design in the literature, our findings should be interpreted cautiously.
Notably, data from a retrospective chart review of patients with nausea and vomiting on high-dose DMP (80 to 120 mg) from 2009 to 2013 under an investigational new drug protocol revealed that despite very high dosing, DMP had a minimal risk of CV adverse events along with good clinical efficacy. 5 Our meta-analysis suggested no significant QT prolongation risk in terms of pre-and posttreatment QT interval values in patients taking DMP.
Similarly, data from a large-scale retrospective chart review revealed prolonged QTc in seven (28.0%) out of 25 patients with a follow-up ECG in a cohort of 66 patients under DMP treatment independent of the daily dose and with no records on palpitations, chest pain, arrhythmias or changes in heart rate and electrolyte disturbances. 5 Nonetheless, it should be noted that a significant heterogeneity was evident for the outcome of the difference between pretreatment and posttreatment means of QT interval in the studies included in our meta-analysis. In addition to data on pre-and posttreatment QT interval, measurements as well as event rates were available in only two studies, 3, 30 necessitating the calculation of these parameters using provided data in five studies, [26] [27] [28] [29] 31 alongside the availability of only event rates with no data on QT measurements in one study. 30 Moreover, patients from included studies showed a wide age scale that ranged from newborns to adults, with evidence on QT prolongation >500 ms in only three studies among pediatric patients; in two out of 22 children aged <2 year, 3 two out of 40 premature infants 28 and one out of 31 newborns, 30 respectively. Hence, while the present meta-analysis revealed no significant QT prolongation with DMP overall, given the individual data from the studies in pediatric patients, our findings seem to emphasize that pediatricians should be aware of potential cardiac side effects of DMP, particularly in case of concurrent risk factors such as prescription of high doses and the presence of concomitant medications that are likely to increase the QT interval or inhibit the P450 enzyme. 3, 42 Notably, only two studies had a ''thorough QT'' (TQT) design in our meta-analysis and both revealed no evidence of QTc prolongation (>500 msc) with any DMP regimen along with mean difference between pretreatment and posttreatment QT intervals of À7.2 and 5.8 ms, respectively. 26, 27 Available data on QT prolongation and cardiac event risk in patients under DMP treatment are largely limited to case reports and case-control studies along with inconsistent findings, 2,4,5,7,10,13-32 and CV risk was evaluated in only one meta-analysis of six studies to date, which revealed current DMP use to increase the risk of VA and SCD by 70%. 4 Hence, our findings emphasize a need for large clinical trials with a longitudinal, prospective design to better address the CV safety profile of DMP overall and in selected patient groups. 2, 5 Nonetheless, our findings emphasize that any risks need to be discussed in detail with patients so they are fully informed.
As a limitation, this meta-analysis was based exclusively on retrospective studies, emphasizing a need for a prospective validation to confirm data provided on DMP-related CV risk. Significant heterogeneity was noted for the outcome of the QT prolongation across included studies, which might have resulted from differences in study designs, patient characteristics and sample sizes and likely influenced the accuracy of our analysis and reduced the statistical power regarding DMP-QT prolongation risk assessment. Consistent with inclusion of studies from large clinical databases, however, classical fail-safe N publication bias tests of moderators indicated large numbers of studies were needed to render the effect size nonsignificant for CV event risk and QT prolongation event rate, indicating that the true effect size of these moderators seems significant enough to allow for certainty in the present meta-analysis.
Conclusion
In conclusion, while overall results of the meta-analysis of nine studies suggest an increased CV event risk in patients under DMP treatment, DMP seems to be associated with increased CV event risk only at doses > 30 mg/day and to offer a more favorable cardiac safety profile than MCP regardless of dosage. A meta-analysis of eight studies suggested no significant QT prolongation risk of event rates and pre-and posttreatment difference in mean QT interval values in patients under DMP treatment. Accordingly, the present meta-analysis seems to indicate that DMP treatment may not be associated with an overall CV event risk increase at doses 30 mg/day and does not result in QT prolongations. Our findings emphasize the need for close monitoring for cardiac events and ECG changes among those on high-dose DMP along with weighing the risk both in the context of clinical decisions and of alternatives. There is a need for well-designed, longitudinal, prospective studies to better address the CV safety profile of DMP overall and in selected patient groups.
